Literature DB >> 31676338

Killer Immunoglobulin-Like Receptor-Ligand Interactions Predict Clinical Outcomes following Unrelated Donor Transplantations.

Elizabeth Krieger1, Roy Sabo2, Sanauz Moezzi1, Caitlin Cain1, Catherine Roberts1, Pamela Kimball3, Alden Chesney4, John McCarty1, Armand Keating5, Rizwan Romee6, Christina Wiedl1, Rehan Qayyum7, Amir Toor8.   

Abstract

Killer immunoglobulin-like receptor (KIR) and KIR ligand (KIRL) interactions play an important role in natural killer (NK) cell-mediated graft-versus-leukemia effect following hematopoietic cell transplantation (HCT). However, there is considerable heterogeneity in the KIR gene and KIRL content in individuals, making it difficult to estimate the full clinical impact of NK cell reconstitution following HCT. Here we present a novel adaptive mathematical model designed to quantify these interactions to better assess the influence of NK cell-mediated alloreactivity on transplant outcomes. Ninety-eight HLA- matched unrelated donor (URD) HCT recipients were studied retrospectively. The KIR-KIRL interactions were quantified using a system of matrix equations. Unit values were ascribed to each KIR-KIRL interaction, and the directionality of interactions was denoted by either a positive (activating) or negative (inhibition) symbol; these interactions were then summed. The absolute values of both the missing KIRL and inhibitory KIR-KIRL interactions were significantly associated with overall survival and relapse. These score components were initially used to develop a weighted score (w-KIR score) and subsequently a simplified, nonweighted KIR-KIRL interaction score (IM-KIR score). Increased w-KIR score and IM-KIR score were predictive of all-cause mortality and relapse (w-KIR score: hazard ratio [HR], .37 [P = .001] and .44 [P = .044], respectively; IM-KIR score: HR, .5 [P = .049] and .44 [P = .002], respectively). IM-KIR score was also associated with NK cell reconstitution post-HCT. KIR-KIRL interactions as reflected by the w-KIR and IM-KIR scores influence both relapse risk and survival in recipients of HLA-matched URD HCT with hematologic malignancies.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HLA-matched unrelated donor; Hematopoietic cell transplantation; Killer immunoglobulin-like receptor; Killer immunoglobulin-like receptor ligand; Mathematical model; Natural killer cell

Year:  2019        PMID: 31676338      PMCID: PMC7190417          DOI: 10.1016/j.bbmt.2019.10.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  40 in total

1.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Authors:  Jeffrey M Venstrom; Gianfranco Pittari; Ted A Gooley; Joseph H Chewning; Stephen Spellman; Michael Haagenson; Meighan M Gallagher; Mari Malkki; Effie Petersdorf; Bo Dupont; Katharine C Hsu
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

2.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Authors:  Katharine C Hsu; Carolyn A Keever-Taylor; Andrew Wilton; Clara Pinto; Glenn Heller; Knarik Arkun; Richard J O'Reilly; Mary M Horowitz; Bo Dupont
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

3.  Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor-Recipient Pairs.

Authors:  Badar Abdul Razzaq; Allison Scalora; Vishal N Koparde; Jeremy Meier; Musa Mahmood; Salman Salman; Max Jameson-Lee; Myrna G Serrano; Nihar Sheth; Mark Voelkner; David J Kobulnicky; Catherine H Roberts; Andrea Ferreira-Gonzalez; Masoud H Manjili; Gregory A Buck; Michael C Neale; Amir A Toor
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-11       Impact factor: 5.742

4.  Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

Authors:  Jeffery S Miller; Sarah Cooley; Peter Parham; Sherif S Farag; Michael R Verneris; Karina L McQueen; Lisbeth A Guethlein; Elizabeth A Trachtenberg; Michael Haagenson; Mary M Horowitz; John P Klein; Daniel J Weisdorf
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

5.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

6.  Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.

Authors:  J Clausen; D Wolf; A L Petzer; E Gunsilius; P Schumacher; B Kircher; G Gastl; D Nachbaur
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

Review 7.  Killer cell immunoglobulin-like receptors on NK cells: the how, where and why.

Authors:  Clair M Gardiner
Journal:  Int J Immunogenet       Date:  2007-12-18       Impact factor: 1.466

8.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.

Authors:  Mark Bosch; Manveer Dhadda; Mette Hoegh-Petersen; Yiping Liu; Laura M Hagel; Peter Podgorny; Alejandra Ugarte-Torres; Faisal M Khan; Joanne Luider; Iwona Auer-Grzesiak; Adnan Mansoor; James A Russell; Andrew Daly; Douglas A Stewart; David Maloney; Michael Boeckh; Jan Storek
Journal:  Cytotherapy       Date:  2012-09-18       Impact factor: 5.414

9.  Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.

Authors:  Kemal Beksac; Meral Beksac; Klara Dalva; Ergun Karaagaoglu; M Bulent Tirnaksiz
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

Review 10.  Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.

Authors:  Christina Rautenberg; Ulrich Germing; Rainer Haas; Guido Kobbe; Thomas Schroeder
Journal:  Int J Mol Sci       Date:  2019-01-08       Impact factor: 5.923

View more
  2 in total

1.  Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.

Authors:  Johannes Schetelig; Henning Baldauf; Linda Koster; Michelle Kuxhausen; Falk Heidenreich; Liesbeth C de Wreede; Stephen Spellman; Michel van Gelder; Benedetto Bruno; Francesco Onida; Vinzenz Lange; Carolin Massalski; Victoria Potter; Per Ljungman; Nicolaas Schaap; Patrick Hayden; Stephanie J Lee; Nicolaus Kröger; Kathy Hsu; Alexander H Schmidt; Ibrahim Yakoub-Agha; Marie Robin
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

Review 2.  Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.

Authors:  Fei Gao; Yishan Ye; Yang Gao; He Huang; Yanmin Zhao
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.